Detection of BRAF mutation in Chinese tumor patients using a highly sensitive antibody immunohistochemistry assay.

Tian Qiu,Lei Guo,Haizhen Lu,Wenting Huang,Ning Lv,Ling Shan,Yun Ling,Jianming Ying,Wenbin Li

doi:10.1038/srep09211

Tian Qiu, Lei Guo + Show 7 more

Open Access

https://doi.org/10.1038/srep09211

Copy DOI

Abstract

BRAF mutations can be found in various solid tumors. But accurate and reliable screening for BRAF mutation that is compatible for clinical application is not yet available. In this study, we used an automated immunohistochemistry (IHC) staining coupled with mouse monoclonal anti-BRAF V600E (VE1) primary antibody to screen the BRAF V600E mutation in 779 tumor cases, including 611 colorectal carcinomas (CRC), 127 papillary thyroid carcinomas (PTC) and 41 malignant melanomas. Among the 779 cases, 150 cases were positive for BRAF (V600E) staining, including 38 (of 611, 6%) CRCs, 102 (of 127, 80%) PTCs and 10 (of 41, 24%) malignant melanomas. Sanger sequencing and real-time PCR confirmed the sensitivity and specificity of IHC staining for the V600E mutation are 100% and 99%, respectively. Therefore, our study demonstrates that the fully automated IHC is a reliable tool to determine BRAF mutation status in CRC, PTC and melanoma and can be used for routine clinical screen.

Highlights

Detection of BRAF mutation in Chinese tumor patients using a highly sensitive antibody immunohistochemistry assay Tian Qiu*, Haizhen Lu*, Lei Guo, Wenting Huang, Yun Ling, Ling Shan, Wenbin Li, Jianming Ying & Ning Lv
Ventana IHC assay using BRAF V600E (VE1) mouse monoclonal primary antibody was performed to screen for the BRAF V600E mutation in 779 patients, including 611 cases of CRC, 127 cases of www.nature.com/scientificreports
A total of 349 patients were analyzed for BRAF mutation by both Sanger sequencing and real-time Polymerase chain reaction (PCR) (Cobas 4800 BRAF V600 Mutation Test), including 181 cases of CRC, 127 cases of papillary thyroid carcinomas (PTC) and 41 cases of malignant melanoma

Summary

Introduction

Detection of BRAF mutation in Chinese tumor patients using a highly sensitive antibody immunohistochemistry assay Tian Qiu*, Haizhen Lu*, Lei Guo, Wenting Huang, Yun Ling, Ling Shan, Wenbin Li, Jianming Ying & Ning Lv. We used an automated immunohistochemistry (IHC) staining coupled with mouse monoclonal anti-BRAF V600E (VE1) primary antibody to screen the BRAF V600E mutation in 779 tumor cases, including 611 colorectal carcinomas (CRC), 127 papillary thyroid carcinomas (PTC) and 41 malignant melanomas. Among the 779 cases, 150 cases were positive for BRAF (V600E) staining, including 38 (of 611, 6%) CRCs, 102 (of 127, 80%) PTCs and 10 (of 41, 24%) malignant melanomas. Our study demonstrates that the fully automated IHC is a reliable tool to determine BRAF mutation status in CRC, PTC and melanoma and can be used for routine clinical screen. Since the discovery in 2002, BRAF mutations have been found in various solid tumors, including thyroid carcinoma, malignant melanoma and colorectal carcinoma. The rate of BRAF mutation increased significantly over a 15-year period

Methods

Results

Conclusion